Market Research Report
Pompe Disease - Epidemiology Forecast to 2030
|Published by||DelveInsight Business Research LLP||Product code||938690|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Pompe Disease - Epidemiology Forecast to 2030|
|Published: May 1, 2020||Content info: 100 Pages||
DelveInsight's 'Pompe Disease (PD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pompe Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Pompe disease (PD), also known as glycogen storage disease type II (GSDII) or "acid maltase deficiency", is caused by the absence or deficiency of acid alpha-glucosidase (GAA), a lysosomal enzyme that is responsible for the cleavage of the α-1, 4- and α-1, 6-glycosidic bonds of glycogen to glucose. The disease is caused pathogenic variations in the acid alpha-glucosidase (GAA) gene. Close to 500 different GAA gene variations have been identified in families with this disorder.
The Pompe Disease (PD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Pompe Disease are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total live birth cases of PD, Total Adult Prevalent cases of PD, Total Prevalent cases of PD, Comorbidities Prevalence of PD by Onset Types, Incidence of IOPD based on clinical phenotypes) scenario of Pompe Disease (PD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
The DelveInsight PD report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
The Pompe Disease Epidemiology report will allow the user to -
Study Period: 2017-2030
Although Pompe disease is a rare autosomal recessive disorder there have been attempts at estimating the overall worldwide incidence with results yielding a value of ~1/40,000. Organizations such as the National Organization for Rare Disorders (NORD) and United Pompe Foundation have also quoted such figures in their publications and journals. However, a fear of underestimation has always prevailed despite adequate precautionary measures due to the inherent difficulty in diagnosis
Newborn screening studies have forced experts to revise previously accepted incidence/prevalence numbers and DelveInsight has kept its focus on these recent happenings while formulating the Epidemiology model for 7 MM